Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Other Medical Devices
beyondair.net

See what CB Insights has to offer

Founded Year

2011

Stage

PIPE | IPO

Market Cap

0.19B

Stock Price

6.77

About Beyond Air

Beyond Air is a medical device and biopharmaceutical company that develops LungFit, a generator and delivery system that produces nitric oxide from ambient air to help with breathing.

Beyond Air Headquarter Location

825 East Gate Blvd Suite 320

Garden City, New York, 11530,

United States

516-665-8200

Latest Beyond Air News

Beyond Air Stock (XAIR): Why The Price Fell This Week

Dec 10, 2021

The stock price of Beyond Air Inc (NASDAQ: XAIR) fell by over 30% this past week. This is why it happened. The stock price of Beyond Air Inc (NASDAQ: XAIR) – a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and through its affiliate Beyond Cancer ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors – fell by over 30% this past week. Investors have been responding negatively to Beyond Air recently announcing an update to the expectations for U.S. Food and Drug Administration (FDA) approval of LungFit PH for the treatment of persistent pulmonary hypertension of the newborn (or PPHN). Based on the ongoing communications with the FDA, the company no longer believes that the U.S. commercial launch of LungFit PH will take place prior to December 31, 2021. And Beyond Air remains on track to receive CE Mark for LungFit PH in Europe in the first half of the calendar year 2022. KEY QUOTE: “The Beyond Air team continues to work towards our goal of bringing LungFit PH, the groundbreaking nitric oxide generator and delivery system, to NICUs across the United States and the world as soon as possible. We commend the FDA for their continued commitment to provide us with a comprehensive review of our application. We shall continue to collaboratively work with the FDA to approve LungFit PH.” — Steve Lisi, Chairman and CEO of Beyond Air Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Beyond Air Patents

Beyond Air has filed 1 patent.

The 3 most popular patent topics include:

  • Cell biology
  • Clusters of differentiation
  • Free radicals
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/30/2020

G protein coupled receptors, Clusters of differentiation, Immune system, Free radicals, Cell biology

Application

Application Date

4/30/2020

Grant Date

Title

Related Topics

G protein coupled receptors, Clusters of differentiation, Immune system, Free radicals, Cell biology

Status

Application

Beyond Air Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Beyond Air Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.